BerriQi for Kids: Boysenberry and apple product for respiratory recovery in kids
BerriQi (Boysenberry and apple product) for post-respiratory infection recovery in primary school-age children in Motueka, NZ
Anagenix
62 participants
Aug 19, 2024
Interventional
Conditions
Summary
Seasonal upper respiratory tract infections are nearly unavoidable, contributing to school absenteeism, employee absenteeism, and reduced quality of life. To our knowledge, all-natural, child-appropriate, non-pharmaceutical, scientifically supported symptom relief is rare. Therefore, this study aims to assess if BerriQi - a natural whole fruit-based product from Boysenberry and apple supports immune and lung health in primary school-age kids with respiratory infections. Validated illness-specific quality of life questionnaire (WURSS-K) will be used to assess the severity and duration of respiratory symptoms for 14 days in children missing school due to upper respiratory tract infection.
Eligibility
Inclusion Criteria4
- Participants and their family are willing and able to give informed consent for participation in the trial.
- -13 years of age.
- Willing to comply with the study protocol .
- Have upper respiratory infection symptoms triggering a school absence.
Exclusion Criteria2
- Allergic to berries
- Not willing to provide informed consent
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
BerriQi is a freeze-dried powder from Boysenberry and apple. Custom chewable tablets are made each containing 500 mg of BerriQi per chewable tablet. Additional ingredients include 500 mg xylitol and 25 mg of magnesium stearate. Each participant will be instructed to consume 2 chewable tablets ( 1000 mg BerriQi) daily for 2 weeks. Participants will self-report on the daily questionnaire if they took BerriQi that day, which will be used as an indicator of adherence.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12624000398505